↓ Skip to main content

Dove Medical Press

Article Metrics

Simeprevir for the treatment of hepatitis C virus infection

Overview of attention for article published in Pharmacogenomics and Personalized Medicine, August 2014
Altmetric Badge

Mentioned by

1 blog
10 tweeters


24 Dimensions

Readers on

44 Mendeley
Simeprevir for the treatment of hepatitis C virus infection
Published in
Pharmacogenomics and Personalized Medicine, August 2014
DOI 10.2147/pgpm.s52715
Pubmed ID

Laure Izquierdo, François Helle, Catherine François, Sandrine Castelain, Gilles Duverlie, Etienne Brochot, Catherine Francois, Francois Helle


Simeprevir (TMC435, Olysio™), a second-generation hepatitis C virus (HCV) protease inhibitor, has been recently approved for the treatment of genotype 1 chronic hepatitis C in combination with pegylated interferon and ribavirin. This molecule has very different characteristics from first-generation protease inhibitors. Results from trials show that simeprevir is highly effective and safe, with few adverse events. We discuss the specific features of this new treatment option for HCV infection, in terms of in vitro data, pharmacological data, and clinical trials. We also discuss the impact of Q80K polymorphism at baseline. Studies evaluating interferon-free regimens with simeprevir are ongoing. Future combinations of two or more direct-acting antiviral agents, targeting different viral enzymes and with synergistic antiviral effects, will be approved, allowing treatment of pan-genotypic HCV with optimized sustained virologic responses. Simeprevir will undoubtedly be part of future treatment strategies.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 2%
Unknown 43 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 18%
Student > Master 8 18%
Researcher 7 16%
Student > Bachelor 6 14%
Student > Doctoral Student 3 7%
Other 7 16%
Unknown 5 11%
Readers by discipline Count As %
Medicine and Dentistry 17 39%
Agricultural and Biological Sciences 8 18%
Biochemistry, Genetics and Molecular Biology 4 9%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Social Sciences 2 5%
Other 4 9%
Unknown 6 14%